Abstract

There are few studies about immunogenicity and safety of heptavalent pneumococcal-CRM197 conjugate vaccine (PCV7) in low birth weight infants. Assessment of immunogenicity following administration of PCV7 in low birth weight children. The PCV7 vaccine was administered to 60 infants divided into two groups: 23 children with birth weight <1000g (Group I); and 37 children with birth weight ≥1000g (Group II). Serum was collected four times. Birth weight of children included in the study ranged from 480g to 2450g. The primary immunization caused an increase in the average concentration of antibodies for all serotypes in most of the participants, with no significant differences between the groups. However, there were some differences between various serotypes. Group serotypes 6B and 23F were the least immunogenic (≥0.35μg/mL, Group I vs. Group II - 6B: 78.3% vs. 67,6% p=0.371 and 23F: 87% vs. 83.8% p=0.738). Prior to the administration of a booster dose, a significant decrease in antibody titer was observed in all children. The last vaccination resulted in an increased concentration of antibodies in all children in both groups, and the results were significantly higher compared to those measured following administration of three doses of the vaccine. PCV7 is immunogenic in children with low, very low, and extremely low birth weight. Serotypes 6B and 23F were the least immunogenic, and serotype 14 proved to be the most immunogenic.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.